Liver fibrosis is the excessive accumulation of extracellular matrix proteins in response to the inflammatory response that accompanies tissue injury, which at an advanced stage can lead to cirrhosis and even liver failure. This study investigated the role of the CXC chemokine CXCL6 (GCP-2) in liver fibrosis. The expression of 
pathogenesis of most types of chronic liver disease. This excessive deposition of ECM proteins at sites of tissue damage, resulting from, for example, viral infection or alcoholic liver disease, is a consequence of a dysregulated wound-healing response. Although reversible if the source of the injury is eliminated, unchecked liver fibrosis can develop into cirrhosis and even liver failure due to portal hypertension, with the only treatment option being transplantation. 1, 2 Chronic liver disease is a major cause of mortality worldwide and correlates with an increased risk of hepatocellular carcinoma. 3 Hepatic stellate cells (HSCs), which are characterized by the storage of retinyl esters in cytoplasmic lipid droplets, constitute around 10% of resident liver cells and in healthy livers are phenotypically non-proliferative and quiescent. However, HSCs are the predominant precursor cells of liver myofibroblasts and upon activation, which is triggered by signalling pathways such as those involving plateletderived growth factor (PDGF) and transforming growth factor-beta (TGF-β), dramatic phenotypic changes are induced accompanied by transdifferentiation into proliferative, inflammatory, fibrogenic myofibroblasts. This process of HSC activation and transdifferentiation is the driver of fibrosis in liver injury. 4 However, the pathways and mediators involved in HSC activation are complex. Understanding the complex regulation of HSC activation is crucial for the development of novel therapeutic strategies to treat liver disease.
TGF-β, which is secreted by several cell types in the liver, is considered the predominant cytokine to trigger HSC activation and fibrogenic transdifferentiation. 5, 6 Kupffer cells (or stellate macrophages) are specialized macrophages that reside in the liver and release proinflammatory and profibrogenic factors such as TGF-β in response to various stimuli (including CXC chemokines), that in turn modulate HSC behaviour and trigger HSC activation. 7 TGF-β-induced de novo synthesis of alpha smooth muscle cell actin (αSMA) fibres enhances the contractility of the cells and increases the expression of ECM proteins for ECM remodelling. 8 TGF-β also binds and phosphorylates the type I receptor, which in turn induces phosphorylation of downstream SMAD proteins, which translocate to the nucleus and activate various mitogen−activated protein kinase (MAPK) signalling pathways to trigger HSC activation and myofibroblast transformation, such as the extracellular signal−regulated kinase (ERK), p38 and c−jun N−terminal kinase (JNK) pathways. [9] [10] [11] [12] [13] Previous studies reported that SMAD proteins can bind to BRD4 in response to TGF-β stimulation. 14 BRD4 is a global regulator of enhancer−mediated profibrogenic gene expression in HSCs. 15 There is evidence from various cancer cell types that BRD4 can interact with the C-MYC promoter and directly regulate its transcriptional expression. [16] [17] [18] Furthermore, recent studies by one research group into the role of BRD4 in bladder cancer reported that BRD4 positively regulates enhancer of zeste homologue 2 (EZH2) transcription through the upregulation of the C-MYC promoter. 19, 20 In this study, the role of CXCL6 (GCP-2) in liver fibrosis was investigated. 
| MATERIALS AND METHODS

| Human serum and liver samples
Serum samples were taken from 50 patients with clinically diagnosed liver fibrosis who had been classified according to fibrotic staging (S) (n = 10 samples for each of the stages: S0, S1, S2, S3 and S4). Liver tissues were taken from 10 patients with clinically diagnosed liver hepatitis who had been classified according to fibrotic staging (S) (n = 6 samples from each of the stages: S0, S1, S2 and S4). All patients were admitted to our hospital from 2013 to 2015. Ethical approval for the study was provided by the independent ethics committee of Shanghai General Hospital, affiliated with Shanghai Jiao Tong University School of Medicine. Informed and written consent were obtained from all patients or their advisors according to the ethics committee guidelines.
| Liver histological observations
Slices of human liver were fixed in 10% phosphate-buffered saline (PBS)-formalin for at least 24 hour and then embedded in paraffin for histological assessment of tissue damage. Samples were subsequently sectioned (5 μm), stained with haematoxylin and eosin (H&E) using standard protocols and then examined microscopically under a light microscope (Olympus Corporation, Tokyo, Japan) to evaluate structural changes indicating liver damage.
| Immunohistochemistry
Liver tissue sections were initially treated by deparaffinization and hydration. Then EDTA (pH 8.0) was added and antigen retrieval was | 5051
| Biochemical analysis
ALT, AST, and hydroxyproline levels were analysed using commercial kits according to the manufacturers' protocols (Nanjing Jiancheng Bioengineering Institute). were used to calculate expression levels after normalization to β-actin, which was used as an internal standard. The primer sequences used in this study are listed in Table 1 .
| Cell culture
| Enzyme-linked immunosorbent assay (ELISA)
The levels of CXCL6, α−smooth muscle actin (α-SMA) and TGF-β in sera or cell culture supernatants were determined using an ELISA kit (Nanjing Jiancheng Bioengineering Institute) according to standard protocols.
| Immunofluorescent staining
Hepatic stellate cells were fixed in 4% paraformaldehyde solution (pH 7.4), blocked in 5% bovine serum albumin (BSA) or 1% BSA with normal serum in 0.1% Triton X-100, and then incubated with primary/secondary antibodies or rhodamine-phalloidin (Cytoskeleton, Denver, CO, USA). The cells were then counterstained with 4ʹ, 6-diamidino-2-phenylindole (DAPI). Images were obtained by fluorescence microscopy at a magnification of 200 × , or using an LSM 510
META laser confocal microscopy system (Carl Zeiss, Jena, Germany).
| Protein isolation and western blot analysis
Hepatic stellate cells or KCs were washed three times with PBS, harvested, and lysed in co-immunoprecipitation (co-IP) buffer, as previously described. 27 The total cell lysate (5 mg protein) was subjected (1:2000) and β-actin (1:5000), were all purchased from Santa Cruz
Biotechnology. The expression levels of proteins were determined using ImageJ software.
| Chromatin immunoprecipitation (ChIP) assay
A ChIP assay was performed using an EZ-ChIP kit (Upstate Biotechnology, Lake Placid, NY, USA), as previously described. 20 Briefly, chromatin DNA was immunoprecipitated with the corresponding antibody or normal IgG. It was then washed and the DNA-protein cross-links were reversed. PCR primers to amplify the C-MYC promotor (forward, 5ʹ-ACATGCTATACACGCACCCC-3ʹ and reverse, 5ʹ-GCTCTCT GCCAGTCTGTACC-3ʹ) and the EZH2 promoter (forward, 5ʹ-TACCCCAACAGTTCATAGGTG-3ʹ and reverse, 5ʹ-GCAGTGCTTATCGCCCTAGA-3ʹ) regions were designed using the Premier Primer 5.0 software and were used in PCR assays to assess the relative amount of immunoprecipitated DNA. A negative control was included to normalize the data.
| Statistical analysis
Statistical analyses were performed using the SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Statistically significant differences were detected using either the Student's t test for comparison between the means or one-way analysis of variance. Data are presented as the mean ± SD and are considered to be statistically significant at *P < 0.05, **P < 0.01, ***P < 0.001, # P < 0.05, ## P < 0.01 and ### P < 0.001.
| RESULTS
| Elevated expression of CXCL6 in the sera and liver tissue of liver fibrosis patients
The sera of liver fibrosis patients categorized as belonging to different fibrotic stages (S1-S4) were analysed biochemically using commercial kits to assess ALT/AST activity and hydroxyproline levels. The serum ALT/AST ratio is a commonly used biomarker of liver health, and hydroxyproline is a major constituent of collagen. Overall, a steady increase in ALT/AST activity and hydroxyproline levels accompanied the progression of liver fibrosis, with the highest levels evident in patients with fibrotic stage S4, as expected ( Figure 1A , P < 0.05 for ALT and AST; Figure 1B , P < 0.001 for hydroxyproline vs the S0 group). Next, serum levels of TGF-β and CXCL6 were determined for the various fibrotic stages. Again, an overall increase in TGF-β and CXCL6 levels was detected with increased fibrotic staging, with the highest levels evident in patients with S4 fibrosis ( Figure 1C , P < 0.01 for TGF-β; Figure 1D , P < 0.01 for CXCL6 vs the S0 group). To con- Figure 3E ). These findings confirmed that exposure of HSCs to KC medium, conditioned by previous exposure to CXCL6, can activate these cells.
| CXCL6 activates HSCs by stimulating TGF-β and its downstream Smad3-BRD4
To determine the pathway by which CXCL6 induces activation of (100 ng/mL) for the indicated times were detected by ELISA and RT-PCR. C, KCs were incubated with CXCL6 (100 ng/mL) for the indicated times, and then cellular EGFR (phospho Y845), total-EGFR, phospho-ERK1/2, total-ERK1/ 2, CXCR1 and CXCR2 protein levels were detected by western blot analysis. D and E, TGF-β concentration and mRNA expression in KCs incubated with CXCL6 (100 ng/mL) or phosphate-buffered saline (PBS) with the addition of CXCR1/2 antagonist SCH527123 (10 μmol/L), EGFR antagonist Afatinib (10 μmol/L), or DMSO as the control, for 18 h were detected by ELISA and RT-PCR. E, Protein levels in KCs incubated with CXCL6 (100 ng/mL) or PBS with the addition of CXCR1/2 antagonist SCH527123 (10 μmol/L), EGFR antagonist Afatinib (10 μmol/L), or DMSO as a control, for 18 h were detected by western blotting (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs 0 h or control group, ## P < 0.01, ### P < 0.001 vs CXCL6 + DMSO group CAI ET AL.
| 5055 EPZ005687, and the cells were cultured for 8 hour. RT-PCR and western blotting analysis revealed that all three inhibitors attenuated α-SMA expression, the BRD4 antagonist JQ1 also attenuated BRD4
and C-MYC expression but not EZH2 expression, the C-MYC antagonist 10058-F4 attenuated C-MYC and EZH2 expression but not BRD4, and the EZH2 antagonist EPZ005687 attenuated EZH2 expression but not BRD4 or C-MYC expression ( Figure 5A and B).
The expression of phosphorylated SMAD3 was downregulated following treatment with all three of the inhibitors ( Figure 5B ).
Next, KCs were treated with CXCL6 for 18 hour, then the KC conditioned medium was transferred onto 3-day HSCs and cultured for 8 hour. Whole cell extracts were immunoprecipitated with SMAD3 antibody or an equal amount of rabbit IgG and blotted with an BRD4 antibody ( Figure 5C ). Exposure to CXCL6 led to the coimmunoprecipitation of the SMAD3 and BRD4 antibodies indicating that CXCL6 stimulates the interaction between Smad3 and BRD4.
Finally, a ChIP assay was performed on the same set of cells using the SMAD3 and BRD4 antibodies ( Figure 5D ). The results indicated that CXCL6 stimulates the direct binding of BRD4 to the C-MYC promoter and C-MYC to the EZH2 promoter, but not BRD4 to the EZH2 promoter.
| Role of CXCL6 verified in a mouse model of chronic liver injury and fibrosis
A mouse model of chronic liver fibrosis was generated by injecting mice regularly with CCl 4 over several weeks (0, 2, 4, 6 and 8 weeks)
to induce high expression of CXCL6 and increasing severity of liver pathology. Experiments were then performed to verify the role of CXCL6 in liver fibrosis in vivo. A steady increase in serum ALT/AST activity accompanied the progression of liver fibrosis in the mice (0-8 weeks of treatment, P < 0.001 at 8 weeks vs the 0 weeks group), indicating deterioration of liver health ( Figure 6A ). Similarly, a steady increase in serum hydroxyproline, TGF-β, CXCL6 levels and F I G U R E 3 CXCL6 Activates Hepatic Stellate Cells via Kupffer Cell Conditioned Medium. A and B, α-SMA and TGF-β concentrations in hepatic stellate cell (HSC)-T6 cells and primary rat HSCs incubated with CXCL6 for the indicated concentrations were detected by ELISA (n = 3). C and D, α-SMA and TGF-β concentrations in HSC-T6 cells and primary rat HSCs incubated with CXCL6 (100 ng/mL) for the indicated times were detected by ELISA (n = 3). E and F, Kupffer cells (KCs) were treated with CXCL6 (100 ng/mL) for 18 h. KC conditioned medium was then transferred onto 3-d HSCs and cultured for the indicated times. α-SMA and TGF-β concentrations in hepatic stellate cell (HSC)-T6 cells and primary rat HSCs were detected by ELISA. G, α-SMA in HSC-T6 cells were cultured with KC conditioned medium was detected by immunofluorescence (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs 0 h group steatohepatitis of liver sections detected by H&E stained was observed, peaking at 6 weeks of treatment (P < 0.001, P < 0.001 and P < 0.01 vs the 0 weeks group, respectively) and slightly decreasing at 8 weeks ( Figure 6B-F) .
The mRNA and protein levels of α-SMA, SMAD3, CXCL6, TGF-β, 
| DISCUSSION
The targeting of signalling pathways that perpetuate myofibroblast activation is a promising therapeutic strategy to combat chronic fibrosis. Fibrosis contributes to the pathogenesis of a number of chronic disorders affecting the liver, kidney, lungs and heart, which collectively account for a substantial proportion of disease-related mortalities in developed countries. 28 Despite recent FDA approval of the first antifibrotic therapies, alternative treatments are needed. To achieve this, an in-depth understanding of the complexities of the activation and transdifferentiation of macrophages into a fibrogenic phenotype is required. Whole cell extracts were immunoprecipitated with SMAD3 antibody or an equal amount of rabbit IgG and blotted with an BRD4 antibody. D, Chromatin immunoprecipitation was performed with the indicated antibodies (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs control group, ## P < 0.01, ### P < 0.001 vs CXCL6 + DMSO group components Smad3-BRD4. Again, using specific antagonists, we depicted that BRD4 could interact with the C-MYC promoter to upregulate its expression, and subsequently enhance the direct binding of C-MYC to the EZH2 promoter. This signalling pathway would lead to the promotion of profibrogenic gene expression, triggering the differentiation of HSCs into a proliferative, fibrogenic form. Our findings were verified in vivo in a mouse model of chronic liver fibrosis.
The elevated expression of CXCL6 in the sera and liver tissue of liver fibrosis patients identified in this study suggests that this chemokine could be an effective marker of liver fibrosis. Synovial macrophages are the major source of most CXC chemokines. However, the specific source of CXCL6 in fibrotic livers remains unclear.
KCs are specialized macrophages that reside in the liver and secrete a variety of proinflammatory and profibrogenic factors such as cytokines, chemokines, prostaglandins, leukotrienes and complement factors in response to various stimuli. 31 Chemokines reported to be released by KCs include CXCL1, CXCL2 and CXCL8, which attract neutrophils, 32 CCL1, CCL2, CCL25 and CX3CL1, which promote the infiltration of bone marrow−derived monocytes, [33] [34] [35] [36] and CXCL16, which attract natural killer T cells. 37 We therefore speculate that activated KCs may be the source of CXCL6 in fibrotic livers and that the CXCL6 secreted by these macrophages, in turn, promotes the release of TGF-β by KCs via the CXCR1/2-EGFR pathway. Kupffer cells reside alongside HSCs in the liver, therefore the secreted TGF-β has profibrogenic effects on neighbouring HSCs.
As stated above, our findings revealed that CXCL6 activated the CXCR1/2-EGFR pathway in KCs. However, interestingly, CXCL6 did not activate HSCs via this same pathway, despite the fact that CXCR1/2-EGFR is also expressed in HSCs. In HSCs, CXCL6 must induce activation via a distinct pathway. This may be investigated further in subsequent studies.
One of the limitations of our study was that we only investigated the secretion of TGF-β in KCs in response to CXCL6. TGF-β is considered the predominant cytokine to trigger HSC activation and fibrogenic transdifferentiation; however, it is possible that CXCL6 may alter the secretion of other fibrosis-related cytokines in KCs.
This should be addressed in future studies. Another limitation was that we did not genetically knock down the expression of liver CXCL6 to confirm its role in promoting the secretion of TGF-β and F I G U R E 6 CXCL6 is Highly Expressed in a Long-Term CCl 4 -Induced Liver Fibrosis Mouse Model. A, Serum ALT/AST activity was detected after mice had been treated with CCl 4 (200 or 300 mg/kg) for 0, 2, 4, 6 or 8 wk. B-D, Serum hydroxyproline, TGF-β and CXCL6 levels were determined. E, Representative images of H&E stained liver sections (×400 magnification). F-H, Relative mRNA and protein levels in the mouse liver tissues were detected by RT-PCR and western blotting (n = 10). *P < 0.05, **P < 0.01, ***P < 0.001 vs 0 wk group activating HSCs in vivo. Future studies analysing the effects of knockdown mutants in the animal model would verify our findings.
In conclusion, our findings reveal the role of CXCL6 in promoting the release of TGF-β by KCs. TGF-β is a potent inducer of HSC activation via a signalling cascade that involves the SMAD2 protein and the BRD4/C-MYC/EZH2 axis. HSC activation and the resulting transdifferentiation into fibrogenic myofibroblasts play a pivotal role in the pathogenesis of liver fibrosis. Our findings, therefore, provide important insight into the complex mechanisms of HSC activation that contribute to liver fibrosis.
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